DOCSLIB.ORG

Phthalates: Toxicology and Food Safety – a Review

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Phthalates: Toxicology and Food Safety – a Review Czech J. Food Sci. Vol. 23, No. 6: 217–223 Phthalates: Toxicology and Food Safety – a Review PŘEMYSL MIKULA1, ZDEŇKA SVOBODOVÁ1 and MIRIAM SMUTNÁ2 1Department of Veterinary Public Health and Toxicology and 2Department of Biochemistry and Biophysics, Faculty of Veterinary Hygiene and Ecology, University of Veterinary and Pharmaceutical Sciences, Brno, Czech Republic Abstract MIKULA P., SVOBODOVÁ Z., SMUTNÁ M. (2005): Phthalates: toxicology and food safety – a review. Czech J. Food Sci., 23: 217–223. Phthalates are organic substances used mainly as plasticisers in the manufacture of plastics. They are ubiquitous in the environment. Although tests in rodents have demonstrated numerous negative effects of phthalates, it is still unclear whether the exposure to phthalates may also damage human health. This paper describes phthalate toxicity and toxicokinetics, explains the mechanisms of phthalate action, and outlines the issues relating to the presence of phthalates in foods. Keywords: di(2-ethylhexyl)phthalate; dibutyl phthalate; peroxisome proliferators; reproductive toxicity Phthalic acid esters, often also called phtha- air, soil, food, etc.). People as well as animals lates, are organic substances frequently used can be exposed to these compounds through in many industries. They are usually colourless ingestion, inhalation or dermal exposure, and or slightly yellowish oily and odourless liquids iatrogenic exposure to phthalates from blood only very slightly soluble in water. Phthalates are bags, injection syringes, intravenous canyllas much more readily soluble in organic solvents, and catheters, and from plastic parts of dialysers and the longer their side chain, the higher their is also a possibility (VELÍŠEK 1999; ČERNÁ 2000; liposolubility and the boiling point. Phthalates LOVEKAMP-SWAN & DAVIS 2003). HAUSER et al. have a broad variety of uses. They are used as the (2004) described abnormally high concentrations so-called plasticisers, i.e. substances that improve of monobutyl phthalate (MBP) in urine of a pa- mechanical properties of plastic materials, mainly tient treated for ulcerative colitis. As part of his PVC. They are also used in the manufacture of therapy, the patient received Asacol tablets for floorings, children’s toys, and are added to printing three months. The tablets with controlled release inks and to perfumes and nail varnishes. Such a were coated with a polymethacrylate film, which broad range of applications in the industry brings was the probable source of phthalates. about the problem of an extensive phthalates – caused contamination of the environment where Toxicity they are nowadays ubiquitous. This is because phthalates are not chemically bound in plastics Acute toxicity of phthalates is very low. Low in any way, and they are relatively easily released molecular phthalates, e.g. diethyl phthalate (DEP), from them to the external environment (water, may cause irritation of the skin, conjunctiva, and Supported by the Ministry of Education, Youth and Sports of the Czech Republic, Project MSM 6215712402. 217 Vol. 23, No. 6: 217–223 Czech J. Food Sci. the mucous membrane of the oral and nasal cavities yet. The authors reported hepatocyte proliferation, in animals. However, similar reactions are not as increased liver weight, and subsequent appear- a rule encountered in humans (API 2001; GÓMEZ- ance of liver tumours in both sexes of rats and HENS & AGUILAR-CABALLOS 2003). mice exposed to high doses of DEHP in food, i.e. Much more important are subchronic and chronic at least 2500 mg/kg of food. toxic effects of phthalates. Most important, numer- ous experiments in rodents have shown adverse Toxicokinetics effects of phthalates on the reproductive system and on the intrauterine development of foetuses. In the case of human exposure to phthalates, EMA et al. (1995, 1996) monitored the effects of phthalate diesters are relatively rapidly hydrolysed monobenzyl phthalate (MBzP) and monobutyl to their respective monoesters in the intestine by phthalate (MBP) administered to female rats dur- pancreatic or liver hydrolases (the first stage of ing pregnancy. It follows from their studies that the phthalate biotransformation). The monoesters exposure to phthalates at doses of about 500 mg/kg thus produced are bioactive molecules responsible during pregnancy may cause in female rats an for the adverse effects of phthalates. Monoesters increase in the number of foetus resorptions and are absorbed in the blood stream and then me- dead foetuses, lower weights of the offspring at tabolised in liver. They are subject in a varying birth and, last but not least, foetus malforma- degree to hydroxylation and oxidation reactions tions, e.g. cleft palate, atresia ani, and skeletal that enhance water solubility of the products. deformations. Phthalate monoesters with a short side chain are Female rats exposed to di(2-ethylhexyl) phtha- oxidised to a lesser extent. The second stage of late (DEHP) at a dose of 2000 mg/kg also dem- phthalate biotransformation is conjugation with onstrated a prolongation in their estrous cycles glucuronic acid mediated by the enzyme UDP-glu- and anovulation as a result of a decrease in serum curonyl transferase. The conjugation affects mainly estradiol levels. The anovulation was related to the monoesters and their oxidised metabolites with a absence of the corpus luteum in the ovary and the long side chain because the conjugation facilitates occurrence of follicular cysts (LOVEKAMP-SWAN the excretion of relatively lipophilic metabolites. & DAVIS 2003). Both the conjugated and the free (non-conjugated) Testicular lesions, hypospadia, cryptorchidism phthalate metabolites are excreted in urine and and other disorders in sexual organs of male rats partly also faeces (SILVA et al. 2003; KATO et al. were also found, which testify to antiandrogenic 2004). effects of some phthalates, particularly of dibutyl Diethyl phthalate (DEP) deviates in some respects phthalate (DBP) and di(2-ethylhexyl) phthalate from the above pattern. On the basis of their meas- (DEHP) (MOORE et al. 2001). Although there are urements, SILVA et al. (2003) assumed that DEP no doubts about adverse effects of phthalates on was absorbed unchanged from the intestine and the reproduction and development in rodents, the was hydrolysed to monoethyl phthalate (MEP) in effects of phthalates on humans have not been kidneys. Because MEP is relatively readily soluble satisfactorily clarified to date. The main reason is in water, it need not be transported to liver for that only very few studies of the effects of phtha- conjugation and is excreted in urine mainly in the lates on humans are available. COLÓN et al. (2000) non-conjugate form. monitored levels of certain phthalates in the blood A mechanism similar to that described in the serum of young Puerto Rican girls aged 6 months human takes place during phthalate metabolism to 8 years with a premature breast development in rodents. A relatively large number of metabo- (thelarche). The authors demonstrated significantly lite types have been reported in urine of rats ex- higher phthalate levels in 68% of patients, which posed to butyl benzyl phthalate (BBP), including suggests possible negative effects of phthalates on phthalic acid, hippuric acid, and trace amounts the human reproduction and development. of benzoic acid. Hippuric acid is a conjugate of Other negative effects of the exposure to phtha- toxic benzoic acid and glycine (NATIVELLE et al. lates may have in rodents are hepatotoxicity and 1999). The conjugation of phthalate metabolites carcinogenicity (DAVID et al. 1999; ELCOMBE et with glucuronic acid takes place in mice only, it al. 2002). These effects have not, however, been practically does not occur at all in rats (ALBRO described in other animal species or the human 1986; NATIVELLE et al. 1999). 218 Czech J. Food Sci. Vol. 23, No. 6: 217–223 Mode of action an increased activity of enzymes participating in the breakdown of estradiol in the liver of fe- Some phthalic acid esters are well-known peroxi- males exposed to DEHP and DBP was confirmed some proliferators (PPs). A very potent peroxisome (LOVEKAMP-SWAN & DAVIS 2003). LOVEKAMP- proliferator is di(2-ethylhexyl) phthalate (DEHP), SWAN and DAVIS (2003) also assumed that the while dibutyl phthalate, butyl benzyl phthalate, female reproductive system may be damaged as and diisononyl phthalate (DBP, BBP, DINP) are a result of processes related to the peroxisome somewhat less effective (VALLES et al. 2003; SEO proliferation mediated not only through PPARα et al. 2004). It should be stressed that adverse ef- but also through PPARγ. fects of diester phthalates are attributable to their The mode of action of the toxic effects of phtha- monoesters produced when diesters are hydrolysed lates to the male reproductive system has not yet in the gastrointestinal tract (HURST & WAXMAN been satisfactorily explained. An impairment of 2003; SILVA et al. 2003). Peroxisome proliferators testosterone metabolism in testes of adolescent are bound by PPARα - PPARδ, i.e. peroxisome pro- male rats has been observed, which is probably due liferator-activated receptors, which they activate to a number of factors. KIM et al. (2004) reported (MELNICK 2001). that testicular impairment and tubular atrophy A role in the process of hepatotoxicity and car- were especially aggravated by hormone regulation cinogenesis is played by subtype PPARα. The ac- disturbances that cause a decrease in the produc- tivated PPARα and the retinoid X receptor (RXR) tion
Load more

Recommended publications
  • The Disposition of Morphine and Its 3- and 6-Glucuronide Metabolites in Humans
    >+'è ,'i5 1. The Disposition of Morphine and its 3- and 6- Glucuronide Metabolites in Humans and Sheep A Thesis submitted in Fulfilment of the Requirements for the Degree of Doctor of Philosophy in Science at the University of Adelaide Robert W. Milne B.Pharm.(Hons), M.Sc. Department of Clinical and Experimental Pharmacology University of Adelaide August 1994 Ar,-,..u i.'..t itttlí I Corrigenda Page 4 The paragraph at the top of the page should be relocated to inimediatèly follow the section heading "1.2 Chemistry" on page 3" Page 42 (lines 2,5 and/) "a1-acid glycoProtein" should read "cr1-acid glycoprotein". Page 90 In the footnote "Amoxicillin" and "Haemacell" should read "Amoxycillin" and "Haemaccel", respectively. Page I 13 (tine -l l) "supernate!' should read "supernatant". ' '(j- Page I 15 (line -9) "supernate" should read "supernatalït1-. Page 135 To the unfinished sentence at the bottom of the page should be added "appears to be responsible for the formation of M3G, but its relative importance remains unknown. It was also proposed that morphine is involved in an enterohepatic cycle." Page 144 Add "Both infusions ceased at 6 hr" to the legend to Figure 6.3. Page 195 (line 2) "was" should fead "were". Page 198 (line l3) "ro re-€xamine" should read "to te-examine". Pages 245 to29l Bibliosraohv: "8r.." should read "Br.". For the reference by Bhargava et aI. (1991), "J. Pharmacol.Exp.Ther." should read "J. Pharmacol. Exp. Ther." For the reference by Chapman et aI. (1984), a full-stop should appear after"Biomed" . For the reference by Murphey et aI.
    [Show full text]
  • Safety Evaluation of Certain Food Additives and Contaminants. WHO Food Additives Series, No
    WHO FOOD Safety evaluation of ADDITIVES certain food additives SERIES: 64 and contaminants Prepared by the Seventy-third meeting of the Joint FAO/ WHO Expert Committee on Food Additives (JECFA) World Health Organization, Geneva, 2011 WHO Library Cataloguing-in-Publication Data Safety evaluation of certain food additives and contaminants / prepared by the seventy-third meeting of the Joint FAO/WHO Expert Committee on Food Additives (JECFA). (WHO food additives series ; 64) 1.Food additives - toxicity. 2.Food contamination. 3.Flavoring agents - analysis. 4.Flavoring agents - toxicity. 5.Risk assessment. I.Joint FAO/WHO Expert Committee on Food Additives. Meeting (73rd : 2010: Geneva, Switzerland). II.World Health Organization. III.Series. ISBN 978 924 166064 8 (NLM classification: WA 712) ISSN 0300-0923 © World Health Organization 2011 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications—whether for sale or for non- commercial distribution—should be addressed to WHO Press at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.
    [Show full text]
  • Glucuronic Acid Derivatives in Enzymatic Biomass Degradation: Synthesis and Evaluation of Enzymatic Activity
    Downloaded from orbit.dtu.dk on: Oct 08, 2021 Glucuronic Acid Derivatives in Enzymatic Biomass Degradation: Synthesis and Evaluation of Enzymatic Activity d'Errico, Clotilde Publication date: 2016 Document Version Publisher's PDF, also known as Version of record Link back to DTU Orbit Citation (APA): d'Errico, C. (2016). Glucuronic Acid Derivatives in Enzymatic Biomass Degradation: Synthesis and Evaluation of Enzymatic Activity. DTU Chemistry. General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. Users may download and print one copy of any publication from the public portal for the purpose of private study or research. You may not further distribute the material or use it for any profit-making activity or commercial gain You may freely distribute the URL identifying the publication in the public portal If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. GLUCURONIC ACID DERIVATIVES IN ENZYMATIC BIOMASS DEGRADATION: SYNTHESIS AND EVALUATION OF ENZYMATIC ACTIVITY PHD THESIS – MAY 2016 CLOTILDE D’ERRICO DEPARTMENT OF CHEMISTRY TECHNICAL UNIVERSITY OF DENMARK ACKNOWLEDGEMENTS This dissertation describes the work produced during my PhD studies. The work was primarily conducted at the DTU Chemistry in the period between November 2012 and January 2016 with an external stay at Novozymes A/S between September 2013 and March 2014.
    [Show full text]
  • Hydrolytic Enzymes Targeting to Prodrug/Drug Metabolism for Translational Application in Cancer
    Journal of Clinical Science & Translational Medicine Hydrolytic Enzymes Targeting to Prodrug/Drug Metabolism for Translational Application in Cancer Prabha M* Review Article Department of Biotechnology, Ramaiah Institute of Technology, India Volume 1 Issue 1 Received Date: April 04, 2019 *Corresponding author: Prabha M, Department of Biotechnology, Ramaiah Institute of Published Date: June 20, 2019 Technology, Bangalore-560054, India, Tel: 080-23588236; Email: [email protected] Abstract A variety of approaches are under development to improve the effectiveness and specificity of enzyme activation for drug metabolism on tumour cell targeting for cancer treatment. Many such methods involve conjugates like monoclonal antibodies, substrate specificity and offer attractive means of directing to tumour toxic agents such as drugs, radioisotopes, protein cytotoxins, cytokines, effector cells of the immune system, gene therapy, stem cell therapy and enzyme therapy for therapeutic use. Hydrolytic enzymes belong to class III of enzyme classification and play an important role in the drug metabolism towards the treatment of cancer. Hydrolases helps drugs for metabolic efficiency to target on cancer cell since it is involved in the hydrolytic reaction of various biomolecules and compounds. The prodrug is designed to be a substrate for the chosen enzyme activity. A number of prodrugs have been developed that can be transformed into an active anticancerous drugs by enzymes of both mammalian and non mammalian origin. The basic molecular biochemistry, biotechnological processes and other information related to enzyme catalysis, has a major impact for the production of efficient drugs. In the current review some of the Hydrolases has been discussed which play a significant role towards prodrug to drug metabolism for cancer treatment.
    [Show full text]
  • In Vitroo and in Vivo Pharmacology of 4-Substituted
    IN VITROO AND IN VIVO PHARMACOLOGY OF 4-SUBSTITUTED METHOXYBENZOYL-ARYL-THIAZOLES (SMART) AND 2- ARYLTHIAZOLIDINE-4-CARBOXYLIC ACID AMIDES (ATCAA) Dissertation Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Chien-Ming Li, M.S. Graduate Program in Pharmacy The Ohio State University 2010 Dissertation Committee: Dr. James T. Dalton, Advisor Dr. Robert W. Brueggemeier Dr. Thomas D. Schmittgen Dr. Mitch A. Phelps Copyright by Chien-Ming Li 2010 ABSTRACT Formation of microtubules is a dynamic process that involves polymerization and depolymerization of the αβ-tubulin heterodimers. Drugs that enhance or inhibit tubulin polymerization can destroy this dynamic process, arresting cells in the G2/M phase of the cell cycle. Although drugs that target tubulin generally demonstrate cytotoxic potency in sub-nanomolar range, resistance due to drug efflux is a common phenomenon among the antitubulin agents. We recently reported a class of 4-Substituted Methoxybenzoyl-Aryl- Thiazoles (SMART), which exhibited great in vitro and in vivo potency. SMART compounds effectively inhibited tubulin polymerization in dose dependent manner, suggesting that SMART compounds may bind to tubulin and subsequently hamper the polymerization. To date the only method to determine the binding of inhibitor to tubulin has been competitive radioligand binding assays. We developed a novel non-radioactive mass spectrometry (MS) binding assay to study the tubulin binding of colchicine, vinblastine and paclitaxel. The method involves a very simple step of separating the unbound ligand from macromolecules using ultrafiltration. The unbound ligand in the filtrate can be accurately determined using a highly sensitive and specific LC-MS/MS method.
    [Show full text]
  • Properties and Kinetic Analysis of UDP-Glucose Dehydrogenase from Group a Streptococci IRREVERSIBLE INHIBITION by UDP-CHLOROACETOL*
    THE JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 272, No. 6, Issue of February 7, pp. 3416–3422, 1997 © 1997 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in U.S.A. Properties and Kinetic Analysis of UDP-glucose Dehydrogenase from Group A Streptococci IRREVERSIBLE INHIBITION BY UDP-CHLOROACETOL* (Received for publication, September 19, 1996, and in revised form, November 6, 1996) Robert E. Campbell‡§, Rafael F. Sala‡, Ivo van de Rijn¶, and Martin E. Tanner‡i From the ‡Department of Chemistry, University of British Columbia, Vancouver, British Columbia V6T 1Z1, Canada and ¶Wake Forest University Medical Center, Winston-Salem, North Carolina 27157 UDP-glucuronic acid is used by many pathogenic bac- the capsule enables the bacteria to evade the host’s immune teria in the construction of an antiphagocytic capsule system (7, 8). Group A and C streptococci are mammalian that is required for virulence. The enzyme UDP-glucose pathogens that use UDPGDH in the synthesis of a capsule dehydrogenase catalyzes the NAD1-dependent 2-fold ox- composed of hyaluronic acid (a polysaccharide consisting of idation of UDP-glucose and provides a source of the alternating glucuronic acid and N-acetylglucosamine residues) acid. In the present study the recombinant dehydrogen- (9, 10). Many of the known strains of Streptococcus pneumoniae ase from group A streptococci has been purified and also use UDP-glucuronic acid in the construction of their po- found to be active as a monomer. The enzyme contains lysaccharide capsule (11), and it has recently been shown that no chromophoric cofactors, and its activity is unaffected UDPGDH is required for capsule production in S.
    [Show full text]
  • Species Differences in the Conjugation of 4-Hydroxy-3-Methoxyphenylethanol with Glucuronic Acid and Sulphuric Acid
    Biochem. J. (1976) 158, 33-37 33 Printed in Great Britain Species Differences in the Conjugation of 4-Hydroxy-3-methoxyphenylethanol with Glucuronic Acid and Sulphuric Acid By KIM PING WONG Department ofBiochemistry, University ofSingapore, Singapore 3 (Received 24 September 1975) The biosynthesis of the glucuronide and sulphate conjugates of 4-hydroxy-3-methoxy- phenylethanol was demonstrated in vitro by using the high-speed supernatant and micro- somal fractions ofliver respectively. These two conjugates were also produced simultane- ously byusingthe post-mitochondrial fraction ofrat, rabbit or guinea-pig liver. In contrast only the glucuronide was synthesized by human liver and only the sulphate by mouse and cat livers. Neither of these conjugates was formed by the kidney or the small or large intestine of the rat. A high sulphate-conjugating activity was observed in mouse kidney; therate ofsulphation of4-hydroxy-3-methoxyphenylethanol with kidney homogenate and high-speed supematant preparations was 1.8 times greater than with liver preparations. The sulpho-conjugates of4-hydroxy-3-methoxyphenylethanol and 4-hydroxy-3-methoxy- phenylglycol were also formed by enzyme preparations ofrabbit adrenal andrat brain; the glycol was the better substrate in the latter system. Mouse brain did not possess any sulphotransferase activity. For the conjugation of 4-hydroxy-3-methoxyphenylethanol by rabbit liver, the Km for UDP-glucuronic acid was 0.22mM and that for Na2SO4 was 3.45mM. The sulphotransferase has a greater affinity for 4-hydroxy-3-methoxyphenyl- ethanol than has glucuronyltransferase, as indicated by their respective Km values of 0.036 and 1.3mM. It was concluded that sulphate conjugation of 4-hydroxy-3- methoxyphenylethanol predominates in most species of animals.
    [Show full text]
  • Drug Metabolism
    Biotransformation of drugs (Drug metabolism ) PharmDr. Pavol Ježko, PhD. Department of Pharmaceutical Chemistry Faculty of Pharmacy, Comenius University Odbojarov 10, 832 32 Bratislava, Slovakia Tel: + 421 250 117 221 e-mail: [email protected] ; [email protected] 1 Biotransformation of drugs • biochemical modification / degradation of drugs • drugs are partially eliminated unchanged or partially biotransformed by metabolic pathways and are excreted as metabolites • biotransformation of drugs influences the deactivation, activation, detoxification, and toxification of the vast majority of drugs 2 OBJECTIVEOBJECTIVE:: conversion of lipophilic drugs to more polar compounds that are easier eliminated 3 XENOBIOTIXENOBIOTICSCS • substances that do not naturally occur in the body (they enter the body), are not necessary for the physiological development and have no nutritional value – drugs – agrochemicals • pesticides, herbicides, fertilizers… – food additives • flavoring agents, coloring agents, preservatives, stabilizers… 4 Places of drug biotransformation • liver: the majority of metabolic reactions • kidney: 2. phase • guts: 2. phase • blood (ester hydrolysis) • plasma (hydrolysis of esters ) within a cell (organels): • endoplasmic reticulum (microsomes) • enzymes cytochrome P450 (CYP-450) • mitochondria • cell cytosol 5 CONSEQUENCES of BIOTRANSFORMATION • bioinactivation : – usually products are less active or inactive metabolites • bioactivation : – in some cases, the metabolic process converts non-active substance on its own active form (prodrug) 6 TYPES OF BIOTRANSFORMATION REACTIONS Biotransformation of drugs takes place in two steps: first phase - functionalization reactions the molecule introduces a new functional group, usually polar (-COOH,-OH,-NH2) the polar group can serve as a reaction point for the second reaction phase second phase - conjugation reactions addition of endogenous molecules (glucuronic, sulphate) to the metabolite of 1.
    [Show full text]
  • X-Ray Fluorescence Analysis Method Röntgenfluoreszenz-Analyseverfahren Procédé D’Analyse Par Rayons X Fluorescents
    (19) & (11) EP 2 084 519 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: G01N 23/223 (2006.01) G01T 1/36 (2006.01) 01.08.2012 Bulletin 2012/31 C12Q 1/00 (2006.01) (21) Application number: 07874491.9 (86) International application number: PCT/US2007/021888 (22) Date of filing: 10.10.2007 (87) International publication number: WO 2008/127291 (23.10.2008 Gazette 2008/43) (54) X-RAY FLUORESCENCE ANALYSIS METHOD RÖNTGENFLUORESZENZ-ANALYSEVERFAHREN PROCÉDÉ D’ANALYSE PAR RAYONS X FLUORESCENTS (84) Designated Contracting States: • BURRELL, Anthony, K. AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Los Alamos, NM 87544 (US) HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR (74) Representative: Albrecht, Thomas Kraus & Weisert (30) Priority: 10.10.2006 US 850594 P Patent- und Rechtsanwälte Thomas-Wimmer-Ring 15 (43) Date of publication of application: 80539 München (DE) 05.08.2009 Bulletin 2009/32 (56) References cited: (60) Divisional application: JP-A- 2001 289 802 US-A1- 2003 027 129 12164870.3 US-A1- 2003 027 129 US-A1- 2004 004 183 US-A1- 2004 017 884 US-A1- 2004 017 884 (73) Proprietors: US-A1- 2004 093 526 US-A1- 2004 235 059 • Los Alamos National Security, LLC US-A1- 2004 235 059 US-A1- 2005 011 818 Los Alamos, NM 87545 (US) US-A1- 2005 011 818 US-B1- 6 329 209 • Caldera Pharmaceuticals, INC. US-B2- 6 719 147 Los Alamos, NM 87544 (US) • GOLDIN E M ET AL: "Quantitation of antibody (72) Inventors: binding to cell surface antigens by X-ray • BIRNBAUM, Eva, R.
    [Show full text]
  • Nucleotide Sugars in Chemistry and Biology
    molecules Review Nucleotide Sugars in Chemistry and Biology Satu Mikkola Department of Chemistry, University of Turku, 20014 Turku, Finland; satu.mikkola@utu.fi Academic Editor: David R. W. Hodgson Received: 15 November 2020; Accepted: 4 December 2020; Published: 6 December 2020 Abstract: Nucleotide sugars have essential roles in every living creature. They are the building blocks of the biosynthesis of carbohydrates and their conjugates. They are involved in processes that are targets for drug development, and their analogs are potential inhibitors of these processes. Drug development requires efficient methods for the synthesis of oligosaccharides and nucleotide sugar building blocks as well as of modified structures as potential inhibitors. It requires also understanding the details of biological and chemical processes as well as the reactivity and reactions under different conditions. This article addresses all these issues by giving a broad overview on nucleotide sugars in biological and chemical reactions. As the background for the topic, glycosylation reactions in mammalian and bacterial cells are briefly discussed. In the following sections, structures and biosynthetic routes for nucleotide sugars, as well as the mechanisms of action of nucleotide sugar-utilizing enzymes, are discussed. Chemical topics include the reactivity and chemical synthesis methods. Finally, the enzymatic in vitro synthesis of nucleotide sugars and the utilization of enzyme cascades in the synthesis of nucleotide sugars and oligosaccharides are briefly discussed. Keywords: nucleotide sugar; glycosylation; glycoconjugate; mechanism; reactivity; synthesis; chemoenzymatic synthesis 1. Introduction Nucleotide sugars consist of a monosaccharide and a nucleoside mono- or diphosphate moiety. The term often refers specifically to structures where the nucleotide is attached to the anomeric carbon of the sugar component.
    [Show full text]
  • Ethyl Glucuronide Homogeneous Immunoassay Ethyl Glucuronide (Etg) Homogeneous Immunoassay
    Ethyl Glucuronide Homogeneous Immunoassay Ethyl Glucuronide (EtG) Homogeneous Immunoassay Randox Toxicology has developed a Homogeneous Immunoassay EtG has been proposed as a marker of recent ethanol intake in (HIA) offering a highly sensitive and accurate toxicology screen a variety of clinical and legal settings, for example in detecting for EtG. EtG is a non-oxidative metabolite of ethanol, formed recent drinking in cases of a negative ethanol test or to confirm by the detoxifying pathway of alcohol elimination via conjugation abstinence from alcohol. with activated glucuronic acid and represents about 0.5% of total ethanol elimination. Randox Toxicology offers unrivalled expertise in Homogeneous Immunoassay reagent optimisation, facilitating exceptional EtG can be detected in body fluids for an extended period of laboratory performance on a variety of clinical chemistry analyzers. time after the elimination of alcohol from the body. In extreme Instrument specific applications are available on all major clinical cases the window of detection in urine could be up to 80 hours. chemistry analyzers and can be provided upon request. Features Cut Off 500 ng/mL Limit of Detection 203.6 ng/mL Overall Agreement 98% correlation with LCMS/MS Negative Agreement Low false negatives - 100% agreement based on a Cut Off of 500 ng/mLEtG Cross–Reactivity No cross–reactivity with EtS Shelf Life 2 years Stability On-board stability of 14 days Kit Format 200 tests/kit and 1650 tests/kit Calibrator Kit Negative Calibrator (0 ng/mL EtG) and Cut Off Calibrator
    [Show full text]
  • Wo 2009/120182 A2
    (12) INTERNATIONALAPPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 1 October 2009 (01.10.2009) WO 2009/120182 A2 (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, A61K 47/34 (2006.01) CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (21) International Application Number: HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, PCT/US2008/013816 KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, (22) International Filing Date: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, 18 December 2008 (18.12.2008) NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, (25) Filing Language: English UG, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 61/015,365 20 December 2007 (20.12.2007) US GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, 12/262,986 31 October 2008 (3 1.10.2008) US ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, (71) Applicant: EASTMAN CHEMICAL COMPANY [US/ ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, US]; 200 South Wilcox Drive, Kingsport, TN 37660 MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (US).
    [Show full text]